Nonetheless, there was a numerical trend favoring the intermediate dose, suggesting potential added benefit in patients at higher risk of progression.
1
—
—
Nonetheless, there was a numerical trend favoring the intermediate dose, suggesting potential added benefit in patients at higher risk of progression.